BC
IMDX

Blackcrane Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Blackcrane Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-149,128
Closed -$5.7M – 9
2020
Q2 		$5.7M Buy
+149,128
New +$7.7M 6.44% 6

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Blackcrane Capital's IMDX Position: Q3 2020 in Review

Blackcrane Capital sold out of Insight Molecular Diagnostics (IMDX) in Q3 2020, closing a stake of 149,128 shares — an estimated $5.7M sold.

Blackcrane Capital first reported a position in IMDX in Q2 2020 and held it in 1 quarter. The position peaked at $5.7M in Q2 2020. 59 funds tracked by Wall St. Rank hold IMDX as of Q3 2020.

  • Blackcrane Capital reported no remaining Insight Molecular Diagnostics position as of Q3 2020 after selling out during the quarter.
  • Blackcrane Capital sold 149,128 Insight Molecular Diagnostics shares in Q3 2020, an estimated $5.7M.
  • Blackcrane Capital first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 1 quarter.
  • Blackcrane Capital's Insight Molecular Diagnostics position peaked at $5.7M in Q2 2020.
  • 59 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2020.

Based on Blackcrane Capital's 13F filing for Q3 2020, filed 12 Nov 2020.